Surgery remans an option for advanced lung cancerJuly 27, 2009MAYWOOD, Il. - In recent years, oncologists have debated whether patients with a certain type of advanced lung cancer would benefit from surgery. Now a major study published in the journal The Lancet has found that surgery after standard chemotherapy and radiation can be an option for patients. Surgery significantly prolongs survival without progression of the lung cancer, but does not dramatically improve overall survival compared to a control group treated with conventional chemotherapy and radiation alone. The patients who did appear to have a major benefit from surgery were those in whom a section of the lung (lobe) was removed, rather than the entire lung, lead author Dr. Kathy Albain and colleagues reported. Albain is a lung and breast cancer specialist at Loyola University Health System's Cardinal Bernardin Cancer Center. "This the first study conducted in this group of patients where the only difference in the two groups of patients was the use of surgery," Albain said. In an accompanying editorial, German researcher Dr. Wilfried Eberhardt and colleagues wrote that as a result of the new study, "We now have clear arguments in favor of surgery in well-selected patient subsets." The study included patients with non-small cell cancer, which accounts for about 80 percent of all lung cancers. Patients had stage 3 cancer, in which the cancer had spread to lymph nodes in the center of the chest. This type of stage 3 cancer accounts for about 30 percent of all non-small cell lung cancer cases. Patients were treated at multiple academic and community hospitals in the United States and Canada. One group of 202 patients was randomly assigned to receive surgery plus chemotherapy and radiation, while a second group of 194 patients received just chemotherapy and radiation. Median overall survival was similar between the two groups: 23.6 months in the surgery group and 22.2 months in the non-surgery group. After five years, 37 patients in the surgical group and 24 patients in the non-surgery group were still alive. The median length of time it took before the cancer began to progress again after treatment was 12.8 months in the surgery group and 10.5 months in the non-surgery group. "Another important finding of our study is that both groups of patients lived longer than previously reporter for this stage of the disease," Albain said. "This highlights the importance of multidisciplinary evaluation and treatment -- which all patients deserve." Loyola University Health System |
|||||||||||||||||||||
| Related Lung Cancer Current Events and Lung Cancer News Articles Researchers Identify Role of Gene in Tumor Development, Growth and Progression Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis. Common pain relief medication may encourage cancer growth Although morphine has been the gold-standard treatment for postoperative and chronic cancer pain for two centuries, a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of cancer cells. Study raises concerns about outdoor second-hand smoke Indoor smoking bans have forced smokers at bars and restaurants onto outdoor patios, but a new University of Georgia study in collaboration with the Centers for Disease Control and Prevention suggests that these outdoor smoking areas might be creating a new health hazard. Carnegie Mellon researchers link health-care debate to risk of dying in US and Europe The current health care debate in the United States is complicated. Trade-offs between heath care expenditures, lifestyle choices and life expectancy have been suggested but seldom clearly demonstrated. PET imaging response a prognostic factor after thoracic radiation therapy for lung cancer A rapid decline in metabolic activity on a PET scan after radiation therapy for non-small cell lung cancer is correlated with good local tumor control, according to a study presented by researchers at Thomas Jefferson University Hospital at the 51st ASTRO Annual Meeting. Study of concurrent radiotherapy, chemotherapy shows promise in small cell lung cancer Treating limited stage small cell lung cancer(LSCL) with a combination of accelerated high-dose radiotherapy and chemotherapy has shown encouraging results. Stereotactic radiotherapy offers noninvasive, effective treatment for frail patients with early-stage lung cancer Stereotactic body radiation therapy (SBRT) should be considered a new standard of care for early-stage lung cancer treatment in patients with co-existing medical problems, according to results from a national clinical trial led by UT Southwestern Medical Center physicians. Preventative brain radiation for lung cancer patients: Benefits and risks A new study is taking a closer look at the benefits versus risks for lung cancer patients to undergo preventative brain radiation therapy as a means to stop cancer from spreading to the brain. Study spotlights efficacy of questionnaire to identify patients at high risk for lung cancer A study featured in the November issue of the Journal of Thoracic Oncology confirms the success of a simple questionnaire designed to identify patients at high risk of lung cancer. Intervals between lung cancer diagnosis and treatment displays a health care disparity Research published in the November 2009 issue of the Journal of Thoracic Oncology has found that intervals between lung cancer suspicion, diagnosis and treatment may be attributed to health care system discrepancies. More Lung Cancer Current Events and Lung Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||